2007 Press Releases
Onyx Pharmaceuticals To Present At UBS Global Life Sciences Conference
EMERYVILLE, CALIF. Sep. 18, 2007
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences conference on Monday, September 24, at 9:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at:
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 27, 2007.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar®, a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar has been approved for the treatment of advanced kidney cancer. For more information about Onyx's pipeline and activities, visit the company's web site at: www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.